Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions
NEW YORK, May 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0491917/Pharmaceutical-Key-Trends-2011-–-Generics-Market-Overview-Patent-cliff-set-to-drive-global-generic-uptake-despite-tougher-market-conditions.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Vitamin_and_Supplement
Introduction
The combined generics market size is valued at approximately $77bn in the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), the BRIC markets (Brazil, Russia, India, and China), and Australia combined. With branded pharma set to lose approximately $100bn in sales due to the patent cliff, this presents a significant opportunity for generics players during 2011–15.
Features and benefits
* An overview generic uptake and market sizing
* Insight into the key drivers and resistors to generic uptake in key the developed and emerging markets.
* An examination of the major generics players and the strategies they have implemented in both the developed and emerging markets.
* Insight into future opportunities for generics players
Highlights
In response to rising healthcare expenditure, governments in developed markets are looking bolster generic uptake in order to contain costs. Physician prescribing by international non-proprietary name (INN), in addition to automatic substitution and pharmacist incentives, are key tools to drive generic uptake.
In the US, despite the addition of many new customers and the continued drive to increase generic uptake as a result of the healthcare reform law, generics companies are set to experience further downward pricing pressures and will be forced to operate with ever-decreasing margins, focusing on consolidation and cost-cutting.
The BRIC countries represent a key growth market for the generics industry. Uptake of generics in these markets will be driven by continued population expansion, increased prosperity, and expanding healthcare coverage.
Your key questions answered
* Evaluate the drivers and resistors to generic uptake in the US, EU, Japan and BRIC markets
* Gain insight into the deal types between companies to bolster their position in generics markets
* Identify which key small molecules are facing patent expiry and provide opportunities for generic producers
Executive Summary
Key findings
Prescription pharmaceuticals sales and growth rate analysis, 2003–15
Operating costs and profit analysis
Shionogi: PharmaVitae forecasts at a glance
Strategic insight
Focus on "core strategic" product lines
Late-stage pipeline products Shionogi's launch portfolio consists of 10 products, six of which have already come to market – Cymbalta, Pirespa (pirfenidone), Rapiacta (peramivir), Kapvay (clonidine hydrochloride), and Cuvposa (glycopyrrolate) – indicating its success in launching late-stage products. Furthermore, over 2009–15, Shionogi plans to file New Drug Applications (NDAs) for at least four late-stage pipeline products (S-349572, S-474474, Ospemifene, and PSD502), and potentially more products if possible.
Global expansion
CNS, ID and CV focus
Decreased emphasis on non-pharmaceuticals business
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure Executive summary
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Key findings
Latest quarterly sales
Q4 2009 Shionogi: rapid Japanese approval represents important milestone for peramivir
Q2 2009
Latest prescription pharma product news
Q3 2010
Q2 2010
Q1 2010
Q4 2009
Q3 2009
Latest corporate news
Q3 2010
Q2 2009
Q1 2009
Q4 2009
Q3 2009
Future product milestones
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history Shionogi and Eli Lilly capsule business
[Missing title]
Current corporate structure
Pharmaceuticals Shionogi is primarily focused on its pharmaceuticals business, which accounts for more than 90% of its total net sales. Crestor (rosuvastatin) is a key contributing product to Shionogi's pharmaceuticals segment. A "superstatin", Crestor, was developed in-house by Shionogi and then out-licensed to AstraZeneca in 1998. AstraZeneca has worldwide marketing exclusivity, except in Japan where the product is co-promoted by the two companies.
Consumer health Shionogi has a small consumer health division, which concerns itself predominantly with the sale of OTC products. These are generally analgesics, antipyretics, vitamins, and minerals. Key products include: the Sedes range‚ a brand of analgesics; Pylon‚ a cold remedy brand; and Popon‚ a family of vitamin compounds. Shionogi has recently expanded its Popon brand‚ adding new formulations to the line. Popon B (muscle fatigue) and Popon Pumeri (eye fatigue) were launched in 2009. In addition to OTC medications‚ Shionogi also markets the Correct brand of denture products.
Diagnostics
COMPANY SALES
Key findings
Prescription pharmaceuticals sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-15
Core analysis, 2009-15
Expiry analysis, 2009-15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Operating costs and profit analysis, 2003–09
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2009–15
KEY PRODUCTS
Key findings
Overview
Cardiovascular
[Missing title]
Irbetan
Central nervous system
[Missing title]
Infectious disease
Flomox
S-349572
APPENDIX
References
Abbreviations
Exchange rates
To order this report:
Vitamin and Supplement Industry: Pharmaceutical Key Trends 2011 – Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions
Vitamin and Supplement Business News
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article